Artivion, Inc.
AORTArtivion, Inc. (AORT) specializes in the development, manufacturing, and distribution of medical devices and tissue products for cardiovascular and general surgical procedures. The company focuses on providing biologic tissue products used in heart valve replacements, vascular grafts, and other surgical interventions, emphasizing regenerative and preservation techniques.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 18, 2015 | $0.03 | 2015-12-09 | 2015-12-11 |
| September 18, 2015 | $0.03 | 2015-09-09 | 2015-09-11 |
| June 19, 2015 | $0.03 | 2015-06-10 | 2015-06-12 |
| March 20, 2015 | $0.03 | 2015-03-11 | 2015-03-13 |
| December 19, 2014 | $0.03 | 2014-12-10 | 2014-12-12 |
Dividends Summary
- Consistent Payer: Artivion, Inc. has rewarded shareholders with 14 dividend payments over the past 3 years.
- Total Returned Value: Investors who held AORT shares during this period received a total of $0.40 per share in dividend income.
- Latest Payout: The most recent dividend of $0.03/share was paid 3865 days ago, on December 18, 2015.
- Yield & Schedule: AORT currently pays dividends quarterly with an annual yield of 0.48%.
- Dividend Growth: Since 2012, the dividend payout has grown by 20.0%, from $0.03 to $0.03.
- Dividend Reliability: AORT has maintained or increased its dividend for 14 consecutive payments.
Company News
Yarger Wealth Strategies made a contrarian bet by acquiring 634,223 shares of Artivion (AORT), making it the fund's largest holding at 9.35% of assets under management. The $25.02 million investment comes as Artivion shares have declined 21.4% over the past year, underperforming the S&P 500 by 46.6 percentage points. The medtech company specializ...
Artivion Inc, a cardiac and vascular solutions company, has received mixed analyst ratings with an average 12-month price target of $43.83. The company shows strong financial performance with impressive revenue growth, net margin, and efficient asset utilization.
Artivion reported strong Q2 2025 financial results, with non-GAAP EPS of $0.24, exceeding expectations and growing 243% year-over-year. Revenue reached $113.0 million, a 15% increase, and the company raised its full-year 2025 guidance.
Artivion, Inc. experienced a data breach on November 20-21, 2024, where an unauthorized third party accessed network files potentially containing sensitive personal information like Social Security Numbers and driver's license details.
The global organ preservation solution market is expected to grow from $273.96 million in 2023 to $536.73 million in 2033, driven by factors such as the rise in organ transplant surgeries, favorable government regulations, and the growing prevalence of chronic diseases. The report highlights key market trends, including strategic investments in R...
